FORTUNE: Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Oct 8, 2026 - P2 | N=48 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial primary completion date: Nov 2026 ➔ Nov 2028
Trial primary completion date • Genito-urinary Cancer • Non Clear Cell Renal Cell Carcinoma • Oncology • Renal Cell Carcinoma • Solid Tumor
|